This potential drug consists of three components: 1) miR-16-based miRNA mimic, 2) drug delivery vehicle composed of non-living bacterial minicells (about 400 nm in size) which allow efficient drug packaging, 3) targeting moiety of nanoparticles to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody (Kara et al., 2022[43]). This evidence concerns the gene EGFR and cancer.